VEGFA and hepatocellular carcinoma: Currently, multi-kinase inhibitors or anti-angiogenic drugs targeting the VEGF/VEGFR signaling pathway, such as sorafenib, lenvatinib, and bevacizumab, have been used in first-line and second-line treatments for HCC.